Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

116

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology has submitted a supplemental NDA to the U.S. FDA for neratinib in combination with capecitabine for the treatment of breast cancer….

 

 

http://www.businesswire.com/news/home/20190701005248/en/Puma-Biotechnology-Submits-Supplemental-New-Drug-Application

- Advertisement -